The Charter:

The ERDITI partnership is based on a charter that provides a streamlined facilitated process of collaboration between academic teams and Pharma Partners to develop drugs for rare diseases.

The charter comprises three parts : a working procedure, a standard material transfer agreement and a standard intellectual property rights agreement.

Participation into the Partnership implies that the Partner agrees to follow in good faith the working procedure and use the standard agreement as a framework for its contractual relationship with other Partners.

The main steps of the procedure

	The academic teams submit to the co-ordinator a proposal for the specific evaluation of chosen molecules in vitro and in animal models
	The scientific advisory board assesses the accuracy of proposals and provide if necessary advice regarding the choice of molecules to be tested
	The co-ordinator questions Pharma Partners on the availability of molecules belonging to pharmacological classes of interest
	If molecules is/are available, a specific agreement is signed between the Pharma Partner, the academic team and the relevant public partner. Transactions with each Pharma Partner are dealt with separately and in confidentiality
	Pharma partners provides the reasonable quantities of molecules required for preclinical studies and the necessary informations for conduct of the studies
	Academic team reports to Pharma Partner the results of the studies carried out with their molecules
	1.The Pharma partners decides to exploit the results of the preclinical studies and undertakes to develop one of the molecules in the treatment of rare disease : the Pharma partner negotiates with the academic team a licence agreement.
	2. The Pharma partners decides not to exploit the results of the preclinical studies : the academic team can select molecules for clinical investigation and the Pharma partner grants necessary licence rights for the development and commercialisation of the molecule in the rare disease field by a third party.